SIRT2 and Parkinson disease: The role of SirT2 in PD is complicated. While reduction of its expression can increase EV release and potentiate disease pathology, sirtuin 2 inhibitors have been shown to block αSyn- mediated toxicity in PD models and thus could be a target for PD therapy [57, 58].